-
-
-
-
-
-
-
Acadia Pharma (ACAD) Appoints Elizabeth H. Z. Thompson as Head of R&D
-
-
-
-
-
-
-
Acadia Pharma (ACAD) Announces Phase 3 Development Candidate ACP-101 for Prader-Willi Syndrome
-
-
-
-
-
-
-
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intrusion, LifeMD, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
-
-
-
-
-
-
-
Pre-Open Movers 11/28: (GPIC) (JILL) (ACAD) Higher; (CHS) (TIF) (SJM) Lower (more...)
-
-
-
-
-
-
-
Pre-Open Movers 06/19: (ASTC) (FMI) (GEVO) Higher; (PAGS) (TELL) (DEA) Lower (more...)
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

